Supplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study | Synapse
September 16, 2024
Supplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study
Key Points
Key points are not available for this paper at this time.
Abstract
Supplementary Figure S2 shows the duration of treatment including response and tumor type (the safety analysis set)
KI fragen
Like
Bookmark
Share
KI fragen
Like
Bookmark
Share
Cite This Study
Meric‐Bernstam et al. (Mon,) studied this question.